Performance-based risk-sharing arrangements - Good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force

Value in Health

Volumn 16, Issue 5, 2013, Pages 703-719

  Garrison, Louis P ^a   Towse, Adrian ^b   Briggs, Andrew ^c   De Pouvourville, Gerard ^d   Grueger, Jens ^e   Mohr, Penny E ^f   Severens, J L ^g   Siviero, Paolo ^h   Sleeper, Miguel ⁱ  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Goldings House   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d ESSEC BUSINESS SCHOOL   (France)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f Center for Medical Technology Policy   (United States)

^g Erasmus Universiteit Rotterdam   (Netherlands)

^h ITALIAN MEDICINES AGENCY   (Italy)

ⁱ GLAXOSMITHKLINE   (United States)

Author keywords

access with evidence development; conditional licensing; coverage with evidence development; managed entry schemes; outcomes based; patient access schemes; pay for performance; performance based risk sharing arrangements; risk sharing

Indexed keywords

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HUMAN; INFORMATION PROCESSING; MEDICARE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; REIMBURSEMENT; RESOURCE ALLOCATION; RISK MANAGEMENT; TELECONFERENCE;

EID: 84881669041     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.04.011     Document Type: Article

References (68)

1. J.J. Carlson, K. Gries, S.D. Sullivan, and L. Garrison PHP146 Current status and trends in performance-based schemes between health care payers and manufacturers Value Health 14 2011 A359 A360
2. J.J. Carlson, S.D. Sullivan, and L.P. Garrison Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers Health Policy 96 2010 179 190
3. Walker S, Schulpher M, Claxton K, et al. Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions. CHE Research Paper 77, University of York, April 2012.
4. G. de Pouvourville Risk-sharing agreements for innovative drugs: a new solution to old problems? Eur J Health Econ 7 2006 155 157
5. J. Hutton, P. Trueman, and C. Henshall Coverage with evidence development: an examination of conceptual and policy issues Int J Technol Assess Health Care 23 2007 425 432
6. A.M. Garber, and M.B. McClellan Satisfaction guaranteed - "payment by results" for biologic agents N Engl J Med 357 2007 1575 1577
7. J.P. Cook, J.A. Vernon, and R. Manning Pharmaceutical risk-sharing agreements Pharmacoeconomics 26 2008 551 556
8. C.J. McCabe, T. Stafinski, R. Edlin, and D. Menon Access with evidence development schemes: a framework for description and evaluation Pharmacoeconomics 28 2010 143 152
9. Department of Health and Ageing, Australian Government. Framework for the introduction of a Managed Entry Scheme for submissions to the Pharmaceutical Benefits Advisory Committee. Available from: http://www.pbs.gov.au/info/ publication/factsheets/shared/framework-for-introduction-of-managed-entry- scheme-for-PBAC-submissions. [Accessed May 2, 2012].
10. M. Klemp, K.B. Fronsdal, and K. Facey What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care 27 2011 77 83
11. A. Towse Value-based pricing, research and development, and patient access schemes: will the United Kingdom get it right or wrong? Br J Clin Pharmacol 70 2010 360 366
12. National Institute for Health and Clinical Excellence. NICE Guidance TA155 Ranibizumab and Pegaptanib for Treatment of Age-Related Macular Degeneration. Manchester, UK: National Institute for Health and Clinical Excellence, 2008.
13. SCRIP. NICE set to recommend Stelara for psoriasis. SCRIP World Pharmaceutical News 17 August 2009. Available from: http://www. scripintelligence.com/policyregulation/NICE-set-to-recommend-Stelara-for- psoriasis-173593. [Accessed 2012].
14. National Institute for Health and Care Excellence. List of technologies with approved Patient Access Schemes, recommended by NICE for use in the NHS. Available from: http://www.nice.org.uk/aboutnice/howwework/paslu/ ListOfPatientAccessSchemesApprovedAsPartOfANICEAppraisal.jsp. [Accessed March 15, 2013].
15. S. Williamson Patient access schemes for high-cost cancer medicines Lancet Oncol 11 2010 111 112
16. UK Department of Health. Patient access schemes and flexible pricing: statement of outcomes from the review of the pricing flexibility measures under Chapter 6 of the 2009 PPRS. Available from: https://www.gov.uk/government/ uploads/system/uploads/attachment-data/file/146829/dh-132794.pdf. [Accessed February 23, 2012].
17. M. Boggild, J. Palace, and P. Barton Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator BMJ 339 2009 b4677
18. R.J. Lilford MS risk sharing scheme: response from chair of Scientific Advisory Committee BMJ 341 2010 c3590
19. L.P. Garrison, E.C. Mansley, and T.A. Abbott Good research practices in cost-effectiveness analyses: a societal perspective: The ISPOR Drug Cost Task Force Report - part II Value Health 13 2010 8 13
20. S.C. Griffin, K.P. Claxton, S.J. Palmer, and M.J. Sculpher Dangerous omissions: the consequences of ignoring decision uncertainty Health Econ 20 2011 212 224
21. A. Towse, and L.P. Garrison Jr Can't get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products Pharmacoeconomics 28 2010 93 102
22. T. Stafinski, C.J. McCabe, and D. Menon Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems Pharmacoeconomics 28 2010 113 142
23. G.S. Zaric, and B.J. O'Brien Analysis of a pharmaceutical risk sharing agreement based on the purchaser's total budget Health Econ 14 2005 793 803
24. K. Chalkidou, A. Hoy, and P. Littlejohns Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research J R Soc Med 100 2007 453 460
25. S. Walker, M. Sculpher, K. Claxton, and S. Palmer Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions Value Health 15 2012 570 579
26. P.E. Mohr, and S.R. Tunis Access with evidence development: the US experience Pharmacoeconomics 28 2010 153 162
27. A. Briggs, K. Ritchie, and E. Fenwick Access with evidence development in the UK: past experience, current initiatives and future potential Pharmacoeconomics 28 2010 163 170
28. L. Levin, R. Goeree, and M. Levine Coverage with evidence development: the Ontario experience Int J Technol Assess Health Care 27 2011 159 168
29. P. Trueman, D.L. Grainger, and K.E. Downs Coverage with evidence development: applications and issues Int J Technol Assess Health Care 26 2010 79 85
30. R. Rettig, P. Jacobson, and C.M. Farquhar False Hope: Bone Marrow Transplantation for Breast Cancer 2007 Oxford University Press New York
31. J.J. Carlson, L.P. Garrison Jr., and S.D. Sullivan Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals J Manag Care Pharm 15 2009 683 687
32. Centers for Medicare & Medicaid Services. Guidance for the Public, Industry, and CMS Staff: National Coverage Determinations with Data Collection as a Condition of Coverage: Coverage with Evidence Development. Baltimore, MD: Centers for Medicare and Medicaid Services, 2006.
33. Centers for Medicare & Medicaid Services. Draft guidance for the public, industry, and CMS staff: coverage with evidence development in the context of coverage decisions. November 29, 2012. Available from: http://www.cms.gov/medicare-coverage-database/details/medicare-coverage- document-details.aspx?MCDId=23. [Accessed March 21, 2013].
34. Palmetto GBA. Jurisdiction 1 Part B. MolDx: coverage with evidence development. Available from: http://www.palmettogba.com/palmetto/providers.nsf/ DocsCat/ Providers~Jurisdiction%201%20Part%20B~Browse%20by%20Topic~MolDx~General~8ZLQQ74 482?open&navmenu=||. [Accessed March 21, 2013].
35. J.A. Turner, W. Hollingworth, B. Comstock, and R.A. Deyo Comparative effectiveness research and policy: experiences conducting a coverage with evidence development study of a therapeutic device Med Care 48 Suppl. 2010 S129 S136
36. E. Garrett, and J.S. Schiff Autism Spectrum Disorders: Report to the Minnesota Commissioner of Human Services 2013 Minnesota Department of Human Services St. Paul
37. S.D. Ramsey, and S.D. Sullivan Evidence, economics, and emphysema: Medicare's long journey with lung volume reduction surgery Health Aff (Millwood) 24 2005 55 66
38. B.E. Hillner, D. Liu, and R.E. Coleman The National Oncologic PET Registry (NOPR): design and analysis plan J Nucl Med 48 2007 1901 1908
39. M.I. Chimowitz, M.J. Lynn, and C.P. Derdeyn [SAMMPRIS Trial Investigators]. Stenting versus aggressive medical therapy for intracranial arterial stenosis N Engl J Med 365 2011 993 1003
40. W. Hollingworth, J.A. Turner, and N.J. Welton Costs and cost-effectiveness of spinal cord stimulation (SCS) for failed back surgery syndrome: an observational study in a workers' compensation population Spine (Phila Pa 1976) 36 2011 2076 2083
41. R. Puig-Peiró, J. Mestre-Ferrandiz, and J. Sussez Literature review on patient access schemes, flexible pricing schemes and risk-sharing agreements for medicines Value Health 14 2011 A233-510, RS1
42. S. Eckermann, and A.R. Willan The option value of delay in health technology assessment Med Decis Making 28 2008 300 305
43. K.P. Claxton, and M.J. Sculpher Using value of information analysis to prioritise health research: some lessons from recent UK experience Pharmacoeconomics 24 2006 1055 1068
44. K. Claxton, S. Palmer, and L. Longworth Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development Health Technol Assess 16 2012 1 323
45. M.L. Berger, N. Dreyer, and F. Anderson Prospective observational studies to assess comparative effectiveness: the ISPOR Good Research Practices Task Force Report Value Health 15 2012 217 230
46. M.L. Berger, M. Mamdani, D. Atkins, and M.L. Johnson Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report - part I Value Health 12 2009 1044 1052
47. M.L. Johnson, W. Crown, and B.C. Martin Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report - part III Value Health 12 2009 1062 1073
48. S. Ramsey, R. Willke, and A. Briggs Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report Value Health 8 2005 521 533
49. M.C. Weinstein, B. O'Brien, and J. Hornberger Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - modeling studies Value Health 6 2003 9 17
50. R.E. Gliklich, M.B. Leavy, and P. Velentgas Incorporating stakeholder perspectives in developing a translation table framework for comparative effectiveness research J Compar Effect Res 1 3 2012 281 292
51. Hefland M, Berg A, Flum D, et al. Draft Methodology Report: "Our Questions, Our Decisions: Standards for Patient-Centred Outcomes Research." PCORI Methodology Committee, Washington, D.C., 2012.
52. S. Eckermann, and A.R. Willan Globally optimal trial design for local decision making Health Econ 18 2009 203 216
53. S. Eckermann, and A.R. Willan Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing Pharmacoeconomics 18 2013 203 216
54. D. Menon, C.J. McCabe, T. Stafinski, and R. Edlin Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit Pharmacoeconomics 28 2010 109 111
55. M. Pickin, C.L. Cooper, and T. Chater The multiple sclerosis risk sharing scheme monitoring study - early results and lessons for the future BMC Neurol 9 2009 1
56. J. Raftery Costly failure of risk sharing scheme BMJ 340 2010 1282 1284
57. M.N. Levine, and J.A. Julian Registries that show efficacy: good, but not good enough J Clin Oncol 26 2008 5316 5319
58. F. Antonanzas, C. Juarez-Castello, and R. Rodriguez-Ibeas Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach Health Econ Policy Law 6 2011 391 403
59. P.P. Barros Pharmaceutical policies in European countries Adv Health Econ Health Serv Res 22 2010 3 27
60. P.P. Barros The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry Health Econ 20 2011 461 470
61. A. Towse, L. Garrison, and R. Puig-Peiro The use of pay for performance for drugs: can it improve incentives for innovation? Occasional Paper 11/05 Office of Health Economics 2012
62. P.J. Neumann, J.D. Chambers, F. Simon, and L.M. Meckley Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement Health Aff (Millwood) 30 2011 2329 2337
63. J. Wlodarczyk, C.M. Reid, and G. Pater Funding linked to ongoing research: impact of the bosentan patient registry on pricing in Australia Value Health 14 2011 961 963
64. L. Coulton, L. Annemans, and R. Carter Outcomes-based risk-sharing schemes: is there a potential role in the Asia-Pacific markets? Health Outcomes Med 3 2012 e205 e219
65. J. Adamski, B. Godman, and G. Ofierska-Sujkowska Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers BMC Health Serv Res 10 2010 153
66. L. Garattini, and G. Casadei Risk sharing agreements: what lessons from Italy? Int J Technol Assess Health Care 27 2011 169 172
67. J. Lexchin Coverage with evidence development for pharmaceuticals: a policy in evolution? Int J Health Serv 41 2011 337 354
68. J. Espin, J. Rovira, and L. Garcia Experiences and impact of European risk-sharing schemes focusing on oncology medicines Eminet January 2011 1 39